Foghorn Therapeutics Inc.’s FHTX share price has dipped by 5.31%, which has investors questioning if this is right time to ...

Eli Lilly and Company (LLY) said on Tuesday that it would acquire California-based private biotechnology company SiteOne ...

Shares of Foghorn Therapeutics Inc. fell more than ... resources to its proprietary pipeline and collaborations with Eli ...

Foghorn Therapeutics has finally given up on ... The phase 1-stage therapy for SMARCA4 mutant cancers is part of an Eli Lilly collaboration originating in 2021, when the Indianapolis Big Pharma ...

Riley has initiated Foghorn Therapeutics (NASDAQ ... which is in development with Eli Lilly (LLY), in late 2025 or early 2026.

Foghorn Therapeutics (NASDAQ ... it has been able to establish a partnership with Eli Lilly (LLY) for the development of FHD-909 and other selective SMARCA drug inhibitors. The purpose of this ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

INDIANAPOLIS, March 25, 2025 /PRNewswire/ -- Eli Lilly and Company ... In an oral presentation, Lilly, in collaboration with Foghorn Therapeutics, will present new preclinical data for LY4050784 ...

Foghorn Therapeutics is working on FHD-909, a selective inhibitor targeting SMARCA2, ... Foghorn’s partnership with Eli Lilly, along with the reiterated price target and rating by Citizens JMP, ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

In JPMorgan's view, CVS's move "will likely impact only a small portion of Eli Lilly's Zepbound business," and the bank therefore believes Lilly stock will still outperform the market. Investment ...